| Literature DB >> 32012914 |
Anca Raluca Dinu1, Alexandru Florin Rogobete1,2, Tiberiu Bratu1, Sonia Elena Popovici1,2, Ovidiu Horea Bedreag1,2, Marius Papurica1,2, Lavinia Melania Bratu1, Dorel Sandesc1,2.
Abstract
Critically ill patients with sepsis require a multidisciplinary approach, as this situation implies multiorgan distress, with most of the bodily biochemical and cellular systems being affected by the condition. Moreover, sepsis is characterized by a multitude of biochemical interactions and by dynamic changes of the immune system. At the moment, there is a gap in our understanding of the cellular, genetic, and molecular mechanisms involved in sepsis. One of the systems intensely studied in recent years is the endocannabinoid signaling pathway, as light was shed over a series of important interactions of cannabinoid receptors with biochemical pathways, specifically for sepsis. Furthermore, a series of important implications on inflammation and the immune system that are induced by the activity of cannabinoid receptors stimulated by the delta-9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) have been noticed. One of the most important is their ability to reduce the biosynthesis of pro-inflammatory mediators and the modulation of immune mechanisms. Different studies have reported that cannabinoids can reduce oxidative stress at mitochondrial and cellular levels. The aim of this review paper was to present, in detail, the important mechanisms modulated by the endocannabinoid signaling pathway, as well as of the molecular and cellular links it has with sepsis. At the same time, we wish to present the possible implications of cannabinoids in the most important biological pathways involved in sepsis, such as inflammation, redox activity, immune system, and epigenetic expression.Entities:
Keywords: CBD; THC; cannabinoids; cannabis sativa; endocannabinoid system; sepsis
Year: 2020 PMID: 32012914 PMCID: PMC7072707 DOI: 10.3390/cells9020307
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Molecular signaling mediated by the endocannabinoid system in the central nervous system. The most important endocannabinoid systems are the anandamide and the 2-arachidonoylglycerol, which also have high concentrations in the brain. Anandamide can be obtained through a series of biological mechanisms that involve the restructuring of phospholipids by the N-acyl-transferases. 2-arachidonoylglycerol results from the action of phospholipase C-beta enzymes or after the dephosphorylation of lysophosphatidic acid. Following these reactions, both anandamide and 2-arachidonoylglycerol activate the G-protein coupled receptors, transient receptor potential vanilloid type 1, and peroxisome proliferator-activated nuclear receptors. Finally, cyclooxygenase-2 can act on these two endocannabinoids through redox mechanisms, leading to the production of prostamides and prostaglandin-glycerol esters. PTLM: lipid precursor phosphatidylethanolamine; NAT: N-acyltransferase; ARa: arachidonic acid; NAPE: N-arachidonoyl-phosphatidylethonolamine; NAPE-PLD: NAPE-phospholipase D; PHa: phosphatidic acid; AEA: anandamide; PTLS: lipid precursor phosphatidylinositol; PLC: phospholipase C; 1,2-DAG: 1,2-diacylglycerol; lysoPI: 2-arachidonoyl-lysophospholipid; DAGL: diacylglycerol lipase; lysoPLC: lysophosphilipase C; 2-AG: 2-arachidonoylglycerol; CB1: cannabinoid receptor 1; CB2: cannabinoid receptor 2; THC: tetrahydrocannabinol; eCANN: endogenous and exogenous cannabinoids; MGL: monoacylglycerol lipase; FAAH: fatty-acid amide hydrolase.
Figure 2Implications of the endocannabinoid system in sepsis. By acting on specific receptors CBD/THC lead to the suppression of cytokine production, as well as to a reduction in redox mechanisms. Through their synergistic action these will lead to the reduction of the systemic inflammatory response and to an immune modulation with neuronal protection. THC: tetrahydrocannabinol; CBD: cannabidiol; CB1: cannabinoid receptor 1; CB2: cannabinoid receptor 2; TRPV: transient receptor potential vanilloid type 1; AEA: anandamide; 2-AG: 2-arachidonoylglycerol; eCBs: endogenous cannabinoids.
Endocannabinoid signaling system as a potential therapeutic target intervention.
| Disorder | Observations | Reference |
|---|---|---|
| Pain | CB1 receptor agonists have a nociceptive action on the interneurons in the spinal cord, CB2 acts directly on reducing inflammation, and the CB2 receptor was shown to have an increased immunomodulatory response. | [ |
| Cancer | The following effects have been reported: Anti-inflammatory, anti-proliferative, pro-apoptotic, anti-invasive, and anti-metastatic. | [ |
| Hepatic metabolism | Directly acts on the modulation of the hepatic metabolism through gluconeogenesis and lipogenesis, and the CB2 receptor has a protective action on the phenomenon induced by ischemia reperfusion injury. | [ |
| Gastrointestinal system | CB1 and CB2 receptors inhibit the pro-inflammatory and pro-oxidative activities specifically for the colon. | [ |
| Cardiovascular system | CB2 receptor reduces inflammation specifically related to atheromatous plaques and reduces thrombosis risk; CB1 activates AMP-activated protein kinase (AMPK), reduces insulin resistance, and mimics all of the effects that encompass ischemia-reperfusion injury (IR). | [ |
| Immune system/inflammation response | Reduces iNOS activity, reduces IL-6 expression; reduces TNF-α and IL-1β expression; reduces specific inflammation of ARDS/ALI; modulates and reduces the activity of TNF-α and COX-2 in the context of LPS-induced inflammation; inhibits neutrophil chemotaxis; and modulates the expression of IFN-γ, leading to the decrease of IL-2 expression. | [ |
ALI: acute lung injury; AMPK: AMP-activated protein kinase; ARDS: acute respiratory distress syndrome; CB1: cannabinoid receptor 1; CB2: cannabinoid receptor 2; COX-2: cyclooxigenase 2; IFN-γ: interferon gamma; IL-1β: interleukin 1 beta; IL-2: interleukin 2; IL-6: interleukin-6; iNOS: NO synthase protein; IR: ischemia-reperfusion injury; LPS: lipopolysachharide; TNF-α: tumor necrosis factor alpha.
Cannabinoids implications on the inflammatory profile and on the immune and redox response.
| Cannabinoid | Observations | References |
|---|---|---|
|
|
↑analgesic effects by FAAH inhibition and ↑AEA expression; ↑inflammation response modulation by TRPA1 as an agonist; By PPARs ↑and ↓in pro-inflammatory expression is obtained; ↓the intensity of neuropathic pain by PPARs; ↑antioxidant effects that lead to ↑protection against redox systems for nerve fibers; ↑anti-proliferative effects on T-cells cellular line; ↓antigen expression on T cells during major infections; ↓CD4+ response in mouse autoimmune myocarditis; ↓CD3+ response in mouse autoimmune myocarditis; ↓myocardial dysfunction in mouse autoimmune myocarditis; ↓leukocyte migration on endothelial cells line; ↑antioxidant expression on J774 cells-LPS stimulus; ↓NO biosynthesis on J774 cells-LPS stimulus; ↓IL-6 production on J774 cells-LPS stimulus; ↓COX-2 expression on J774 cells-LPS stimulus; ↓inflammation and cytokine production on alveolar macrophages; | [ |
|
|
Through stimulation CB2 ↓pain-related inflammation modulate the serotonin biochemical pathways; TRPA1 activation modulate the inflammatory response; ↓inflammation and neuropathic pain through modulation of PPARs; ↓T cell expression and proliferation on T cells—cellular line; ↓IL-2 biosynthesis on T cells—cellular line; ↓IFN-γ biosynthesis on T cells—cellular line; ↓intestinal tissue injury on murine acute graft versus host disease (GVHD) model; ↓mortality on murine acute GVHD model; Prevent weight loss on murine acute GVHD model; | [ |
FAAH: fatty-acid amide hydrolase; AEA: anandamide; TRPA1: transient receptor potential cation channel, subfamily A, member 1; PPARs: peroxisome proliferator-activated receptors; CD4+: cluster of differentiation 4; CD3+: cluster of differentiation 3; LPS: lipopolysachharide; NO: nitric oxide; IL-6: interleukin 6; IL-2: interleukin 2; COX-2: cyclooxigenase 2; CB2: cannabinoid receptor 2; IFN-γ: interferon gamma; GVHD model: models of graft-versus-host disease; ↓ - increase; ↑ - decrease.
Figure 3Implications of THC/CBD on the immune response modulation in infections. THC/CBD is responsible for the inhibition of TNF-α, NF-kB and IFN-γ (a* [177]) production. This process takes place through the initial inhibition of Th1 and through the decrease in the expressions of IL-6, TNF-α, and IL-1β by modulating the activity of macrophages (a,b* [177,178]), neutrophils (a,b* [177,178]) and Th cells. THC/CBD: tetrahydrocannabinol/cannabidiol; IFN-γ: interferon gamma; TGF-β: transforming growth factor beta; TNF-α: tumor necrosis factor alpha; IL-1β: interleukin 1 beta; IL2: interleukin 2; IL-4: interleukin 4; IL-5: interleukin 5; IL-6: interleukin 6; IL-10: interleukin 10; ROS: reactive oxygen species; NO: nitrogen oxide; DC: dendritic cells; Th cells: T helper cells.